AnaCardio raised €62.5 million (about $70.9 million) in a Series B to advance its chronic advanced heart failure program toward registrational development. The Stockholm-based biotech said the funding is designed to extend its runway “well into” the next stage of work. The financing comes as the company prepares to scale development efforts for a heart failure therapy positioned as potentially safer than existing options, aiming to differentiate on tolerability and usability for chronic patient populations. While public details on the clinical readouts were limited in the filing snapshot, the magnitude of the Series B signals investor willingness to fund late preclinical-to-registrational transition when a clear path to efficacy evidence is articulated. For AnaCardio, the next catalyst is likely completion of studies needed to support regulatory engagement, where payer and clinical differentiation in chronic heart failure will depend heavily on safety profile and demonstrated improvement in functional outcomes.